Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Risk Categories for Patients with Atypical CML Evaluated

Am J Hematol; 2017 Jun; Patnaik, Barraco, et al

It may be useful to group patients with atypical chronic myeloid leukemia (aCML) into certain risk categories, according to a study involving 25 individuals.

Participants—all with aCML—were a median of 70 years of age. All had gene mutations, and more than one-third had cytogenetic abnormalities. Among the results:

  • Median overall survival was ~11 months.
  • At a median follow-up of 11 months, 68% had died, and 8% experienced leukemic transformations.
  • Survival was adversely impacted by advanced age; low hemoglobin; red blood cell transfusion dependence; high white blood cell count; TET2, NRAS, PTPN11 mutations; and the presence of ≥3 gene mutations.
  • In multivariable analysis, age >67; low hemoglobin; and TET2 mutations retained prognostic significance.

Citation:

Patnaik M, Barraco D, Lasho T, et al. Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. Am J Hematol. 2017;92(6):542-548. doi:10.1002/ajh.24722.